Gyre Therapeutics Releases Q1 2026 Financial Results

[ad_1] AlphaStreet Newsdesk powered by AlphaStreet Intelligence GYRE|EPS -$0.10|Rev $22.5M|Net Loss $9.9M Gyre Therapeutics, Inc. (GYRE) reported an adjusted loss of $0.10 per share for the first quarter of 2026, as the pharmaceutical company continues developing its pipeline of anti-inflammatory…